2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i j k l m [n] o p q r s t u v w x y z

Abstract Number: 1909

Nailfold Capillaroscopic Assessment and Vascular Biomarkers in Systemic Sclerosis: Low CD40L Levels in Patients with Late Scleroderma Patterns
Abstract Number: 308

Nailfold Capillaroscopy in Patients with Early Onset-Dermatomyositis
Abstract Number: 969

Namilumab, an Anti-Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Monoclonal Antibody: Results of the First Study in Patients with Mild-to-Moderate Rheumatoid Arthritis (RA)
Abstract Number: 3082

Nanogel Based Delivery of an Inhibitor of Calcium/ Calmodulin- Dependent Protein Kinase 4 Suppresses Experimental Autoimmune Encephalomyelitis and Lupus-like Disease in Mice
Abstract Number: 854

Nationwide Incidence of Anti Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis in Iceland
Abstract Number: 1083

Nationwide Trends in Hospitalization and in-Hospital Mortality Associated with Granulomatosis with Polyangiitis (GPA)
Abstract Number: 846

Nationwide Trends in in-Hospital Mortality and Hospitalization Associated with Systemic Sclerosis (SSc)
Abstract Number: 843

Natriuretic Peptide Predicts Mortality in Systemic Sclerosis
Abstract Number: 1366

Natural Antibodies, Not B Cells, Contribute to Acute Cell Death-Induced Inflammation
Abstract Number: 2710

Necrox-7 Inhibits Cell Aggressiveness By Suppressing of NF-Kappa B Activation and Reactive Oxygen Species Generation in Human Rheumatoid Arthritis Fibroblast-like Synoviocytes
Abstract Number: 167

Negative Gaenslen’s (Squeeze) Test Has a High Negative Predictive Value for Significant Ultrasonographic Metatarsophalangeal Involvement in Early Arthritis
Abstract Number: 2833

Negative Regulator, MiR-23a, Down-Regulated in Psoriatic Arthritis. Implications for Disease Pathogenesis
Abstract Number: 292

Neoepitope Biomarkers As Biomarkers of Polymyositis and Dermatomyositis and Functional Status
Abstract Number: 2527

Neonatal Outcome to Paternal Exposures with Anti-Rheumatic Therapy
Abstract Number: 3190

Netrin-1 and Its Receptor Unc5b Are Novel Targets for the Treatment of Inflammatory Arthritis
Abstract Number: 2089

Netrin-1 and Its Receptors Unc5b and DCC May be Useful Targets for Preventing Multiple Myeloma Bone Lesions
Abstract Number: 2848

Network Meta-Analysis of Tumor Necrosis Factor, Interleukins, and Phosphodiesterase-4 Inhibitor in the Treatment of Psoriatic Arthritis
Abstract Number: 1451

Neurologic Findings and Serial Neuroimaging in Patients with Linear Scleroderma En Coup De Sabre (ECDS) and Parry-Romberg Syndrome (PRS)
Abstract Number: 761

Neurometabolic Alterations in Korean Lupus Patients with Chronic Daily Headache
Abstract Number: 1434

Neuropathic Pain in Patients with Rheumatoid Arthritis: Relation with Clinical Variables
Abstract Number: 569

Neurophil to Lymphocyte Ratio Is a Reliable Marker of Treatment Response in Rheumatoid Arthritis Patients during Tocilizumab Therapy
Abstract Number: 964

Neutrophil Extracellular Traps Are Not Only Targets for ACPA-Positive IgG from Rheumatoid Arthritis Patients but Also Directly Trigger Pro- and Anti-Inflammatory Effects Partly Mediated By the C1q Complement Protein
Abstract Number: 2598

Neutrophil Extracellular Trap Levels Measured By Cell Free Nucleosome ELISA in Serum Are Highly Specific and Sensitive for Rheumatoid Arthritis
Abstract Number: 1530

Neutrophil Function and Survival Unaffected in Healthy Subjects Following Single Administration of Tocilizumab
Abstract Number: 1763

Neutrophil Netosis Formation during the UVB Induced-Skin Inflammation
Abstract Number: 2704

Neutrophil-Derived Lactoferrin Regulates the Activity of NFAT5 in Rheumatoid Arthritis Synovial Fibroblasts Via Toll-like Receptor 4
Abstract Number: 208

Neutrophil-Mediated Mechanisms of Drug-Induced Autoimmunity
Abstract Number: 860

Neutrophil/Lymphocyte Ratio: Could It be a Prognostic Indicator for Renal Outcome in Patients with Granulomatosis with Polyangiitis?
Abstract Number: 2174

Neutrophils in Primary Antiphospholipid Syndrome Are Characterized By a Prominent Activated Phenotype and Uniquely Remodeled Chromatin Architecture
Abstract Number: 1407

New Clinical Features of Pyogenic Arthritis, Pyoderma Gangrenosum, and Acne Syndrome
Abstract Number: 2229

New Frontiers: Teaching Quality Improvement to First Year Medical Students in a Rheumatology Safety Net Clinic
Abstract Number: 3176

New Prospects for Interpreting Bony Depressions in Juvenile Idiopathic Arthritis: A Novel MRI Computer-Assisted Technique for Detection of Erosive Progression
Abstract Number: 101

New Technologies for Typing Self-Identifying Antigens Encoded By HLA Genes Provide Cost-Effective Alternatives to Identifying B27 Allele Status in Rheumatoid Arthritis Subjects
Abstract Number: 371

New Vertebral Fractures after Vertebroplasty: Two Year Results from a Randomised Placebo-Controlled Trial
Abstract Number: 1125

Next-Generation Sequencing Demonstrates Dynamic Recirculation of B Cell Clones in Ectopic Lymphoid Structures of Sjögren’s Syndrome
Abstract Number: 94

NGS Panel for the Detection of Monogenic SLE in Children: Initial Results
Abstract Number: 2153

Nintedanib Ameliorates Fibrotic and Vascular Manifestations in Preclinical Models of Systemic Sclerosis
Abstract Number: 2547

NIP-565, a Novel JAK1-Selective Inhibitor, for the Treatment of Rheumatoid Arthritis
Abstract Number: 848

Nitroglycerin Patch Application in Systemic Sclerosis: Evaluation By Laser Doppler Imaging
Abstract Number: 3058

NMR-Based Metabolomics Provides New Insights into the Inflammatory Processes in Takayasu Arteritis
Abstract Number: 1594

No Association of Anti-Citrullinated Peptide Antibodies with Coronary Artery Calcification in Two Rheumatoid Arthritis Cohorts without Clinical Cardiovascular Disease
Abstract Number: 2686

No Clear Association Between the Presence of Ultrasound Synovitis and Patient Reported Outcomes in Rheumatoid Arthritis Patients in Remission
Abstract Number: 2499

No More No Shows: Improving the Appointment Reminder System at an Urban County Hospital Outpatient Rheumatology Clinic
Abstract Number: 454

No Sex Bias in the Escalation of Therapy in the Treatment of Early Inflammatory Arthritis
Abstract Number: 64

Nociceptive Flexion Reflex Threshold: Possible Surrogate Marker of Symptom Severity in Fibromyalgia
Abstract Number: 940

NOD2-Associated Autoinflammatory Disease: Therapy and Outcomes
Abstract Number: 498

Non-Adherence to Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: An Italian Survey
Abstract Number: 2184

Non-Criteria Clinical Manifestations in Antiphospholipid Syndrome: Clinical Behavior and Association with Damage Accrual
Abstract Number: 1629

Non-Interventional Clinical Study Investigating the Use of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis in Germany – 3rd Interim Analysis
Abstract Number: 2855

Non-Response to Antitnf Treatment in Psoriatic Arthritis Can be Predicted By an Objective Automated Measurement of Fluorescence-Signal Intensities in Fluorescence-Optical Imaging Technique – the First Interims Analysis of the Xplore-Study
Abstract Number: 1767

Noninvasive Assessment of Macrophage Activation in Experimental Glomerulonephritis Using Optical Imaging with Near-Infrared Light Serves As a Surrogate of Disease Activity
Abstract Number: 2034

Nontuberculous Mycobacterial Diseases Do Not Cause Positive Autoantibody Testing, Results from a Tertiary Pulmonary Care Center
Abstract Number: 2782

Not Only 5 but Also 6 Weeks Intervals of Tocilizumab Infusion Induce Clinical Remission in Patients with Active Rheumatoid Arthritis
Abstract Number: 2792

Not Only Sjögren’s Syndrome. EBV Infection Reactivation As a Risk Factor of the Dryness Symptome Development
Abstract Number: 901

Novel B Cell-Derived Peptide Regulation of Homeostatic T-Cell Trafficking Is Subverted in Rheumatoid Arthritis
Abstract Number: 1150

Novel Chitosan Hydrogels for the Treatment of Osteoarthritis: Mechanical Support, Lubrication and Prevention of Cartilage Degradation in a Rabbit Model of Osteoarthritis
Abstract Number: 1033

Novel Ligand-Independent Peptide Inhibitors of Triggering Receptor Expressed on Myeloid Cells 1 (TREM-1) and T Cell Receptor (TCR): Efficacy in a Collagen-Induced Arthritis Model Suggests New Targeted Treatment for Rheumatoid Arthritis
Abstract Number: 1813

Novel Mechanism of Action of Anti-Malarial Drugs in the Inhibition of Type I Interferon Production
Abstract Number: 2773

Novel Mechanisms of Action for Methotrexate and Doxycycline: Prevention of Protein Adduct Formation and Free Radical Scavenging
Abstract Number: 2566

Novel Therapeutic Compound Tuftsin-Phosphorylcholine Attenuate Collagen Induced Arthritis
Abstract Number: 946

Novel Tripartite Motif Proteins Linked to Membrane Integrity As Biomarkers of Dermatomyositis and Polymyositis
Abstract Number: 2988

Novel Use of Musculoskeletal Ultrasound (MSUS) to Measure Ulcers in the Skin of Systemic Sclerosis (SSc) Patients.
Abstract Number: 2564

Nuclear Receptor 4A2 Is Selectively Upregulated in the Human TNF-Alpha Transgenic Model of Rheumatoid Arthritis
Abstract Number: 1021

Nucleic Acids Sensing Receptors RIG-I and MDA5 As Potential Amplifiers of the Interferon Signature in Childhood Onset Systemic Lupus Erythematosus

Jump to: View All • a b c d e f g h i j k l m [n] o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].